Academic Journal
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients
| العنوان: | Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients |
|---|---|
| المؤلفون: | Zavrelova, Alzbeta, Sima, Martin, Malakova, Jana, Rozsivalova, Petra, Paterova, Pavla, Zak, Pavel, Visek, Benjamin, Michalickova, Danica, Slanar, Ondrej, Radocha, Jakub |
| المساهمون: | Univerzita Karlova v Praze |
| المصدر: | British Journal of Clinical Pharmacology ; volume 89, issue 4, page 1452-1461 ; ISSN 0306-5251 1365-2125 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2022 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Aim The objective of this study was to evaluate off‐label high‐dose ceftazidime population pharmacokinetics in cancer patients with suspected or proven extensively drug‐resistant (XDR) Pseudomonas aeruginosa infections and then to compare the achievement of the pharmacokinetic/pharmacodynamic (PK/PD) target after standard and off‐label high‐dose regimens using population model‐based simulations. A further aim was to clinically observe the occurrence of adverse effects during the off‐label high‐dose ceftazidime treatment. Methods In patients treated with off‐label high‐dose ceftazidime (3 g every 6 h), blood samples were collected and ceftazidime serum levels measured using LC–MS/MS. A pharmacokinetic population model was developed using a nonlinear mixed‐effects modelling approach and Monte Carlo simulations were then used to compare standard and high‐dose regimens for PK/PD target attainment. Results A total of 14 cancer patients with serious infection suspected of XDR P. aeruginosa aetiology were eligible for PK analysis. XDR P. aeruginosa was confirmed in 10 patients as the causative pathogen. Population ceftazidime volume of distribution was 13.23 L, while clearance started at the baseline of 1.48 L/h and increased by 0.0076 L/h with each 1 mL/min/1.73 m 2 of eGFR. High‐dose regimen showed significantly higher probability of target attainment (i.e., 86% vs . 56% at MIC of 32 mg/L). This was translated into a very low mortality rate of 20%. Only one case of reversible neurological impairment was observed. Conclusion We proved the superiority of the ceftazidime off‐label high‐dose regimen in PK/PD target attainment with very low occurrence of adverse effects. The off‐label high‐dose regimen should be used to optimize treatment of XDR P. aeruginosa infections. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1111/bcp.15612 |
| الاتاحة: | http://dx.doi.org/10.1111/bcp.15612 https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15612 https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bcp.15612 https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15612 |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.3471B2CC |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/bcp.15612 |
|---|